ABSTRACT Forty two patients with inoperable non-small cell lung cancer were entered into a phase II study of the combination chemotherapy regimen PVB (cisplatin 60 mg/M2 by intravenous Cisplatin has been combined with another vinca alkaloid, vinblastine, producing a response rate similar to that for cisplatin with vindesine.'8 '9 At the start of this study, the combination of cisplatin, vinblastine and bleomycin (PVB) had been reported to be highly successful in the treatment of germ cell tumours20 and it was reported subsequently to be of use in the treatment of adenocarcinoma of unknown primary site.2' Furthermore, phase II studies with PVB had been initiated in our institutes for cervical cancer and head and neck cancer, and these showed the activity of this regimen.22 We decided therefore to investigate the role of PVB in the management of inoperable non-small cell lung cancer.
The results of chemotherapy in the treatment of non-small cell lung cancer have been disappointing, especially when compared with the high response rates and prolongation of survival which chemotherapy may produce in the treatment of small cell lung cancer.'2 Most single agents active against non-small cell lung cancer induce response in less than 20% of patients34 and combination chemotherapy has led to little improvement in response rates or survival.5-8 Cisplatin in one of the more active single agents, producing a cumulative response rate of 19% from published series.9 1'3 The combination of vindesine with cisplatin appears to increase the response rate'4 's and one study noted that the median survival for responding patients receiving high dose cisplatin and vindesine was 22 months. ' Accepted 12 November 1984 Cisplatin has been combined with another vinca alkaloid, vinblastine, producing a response rate similar to that for cisplatin with vindesine.'8 '9 At the start of this study, the combination of cisplatin, vinblastine and bleomycin (PVB) had been reported to be highly successful in the treatment of germ cell tumours20 and it was reported subsequently to be of use in the treatment of adenocarcinoma of unknown primary site.2' Furthermore, phase II studies with PVB had been initiated in our institutes for cervical cancer and head and neck cancer, and these showed the activity of this regimen. 22 We decided therefore to investigate the role of PVB in the management of inoperable non-small cell lung cancer.
Methods

PATIENTS
From October 1979 to May 1983, 42 patients with inoperable non-small cell lung cancer, from two institutions, were entered into the study after informed consent had been obtained. Thirty three were male and nine female; the median age was 56 years (range 41-74 years). All Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer our experience with the PVB regimen, treatment was accompanied by frequent and often severe toxicity and the survival benefit for responders was only six months-somewhat less than that reported in patients receiving high dose cisplatin and vindesine. '5 Aisner and Hansen emphasised the importance of low performance capacity, extensive disease, and prior weight loss as adverse prognostic factors in the treatment of non-small cell lung cancer.30 In the present study performance score and extent of disease were not important prognostic factors influencing outcome, although no prior weight loss, no prior radiotherapy, and possibly the presence of the squamous cell type appeared to be associated with an increased likelihood of response to treatment and increased survival. The small numbers in each subgroup do not, however, allow firm conclusions to be drawn.
In any trial of palliative chemotherapy in advanced malignant disease it is important to weigh the benefits of treatment, such as improvement in symptoms and possibly survival, in responding patients against the toxic effects experienced by all patien,ts. This is particularly important for non-small cell lung cancer, where response rates are usually relatively low and survival is short. Only two series have so far been reported in which chemotherapy has been compared with placebo in patients with non-small cell lung cancer.3' 32 Although the results of both indicated a survival benefit for patients responding to chemotherapy this might reflect the better performance status of patients subsequently achieving a response, and further randomised studies of chemotherapy versus no chemotherapy in the management of non-small cell lung cancer will be necessary to establish clearly which subgroups of these patients may benefit from chemotherapy.
Meanwhile the conclusion is that platinum based combination chemotherapy is a toxic form of treatment which causes tumour regression or palliation in only about one third of patients.
